Pennsylvania-based BioLeap, which uses computational FBDD, has just signed a deal with GlaxoSmithKline to work on “difficult” targets. The announcement came September 8, just a month after BioLeap started a collaboration with Lycera on autoimmune disorders. I haven’t personally seen any talks or papers out of BioLeap, but there have certainly been plenty of improvements in computational chemistry applied to FBDD recently (see here, here, and here), and given the lag between discovery and disclosure there are likely many new developments.
This is also the second fragment deal that GSK has done in the past month; we already noted their collaboration with Vernalis.
What do you think? Does this flurry of new deals signify increasing use of FBDD?
Posts
No comments:
Post a Comment